The substantial increase in short interest for Pieris Pharmaceuticals suggests that investors are becoming more bearish on the stock. However, being below the peer average might mitigate some negative perceptions. The short-term impact is likely negative due to increased bearish sentiment, but the below-average peer comparison could provide some buffer against a steep decline.